Boothbay Fund Management’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Boothbay Fund Management’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,499	Closed	-$134K	–	2642
2022 Q3	$134K	Hold	13,499	–	–	﹤0.01%	1971
2022 Q2	$132K	Hold	13,499	–	–	﹤0.01%	1914
2022 Q1	$132K	Hold	13,499	–	–	﹤0.01%	2038
2021 Q4	$131K	Buy	13,499 +400	+3%	+$227	﹤0.01%	1655
2021 Q3	$127K	Buy	13,099 +400	+3%	+$269	﹤0.01%	1750
2021 Q2	$123K	Buy	+12,699	New	+$7.71K	﹤0.01%	1702

Other funds holding IBER.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Boothbay Fund Management's IBER.WS Position: Q4 2022 in Review

Boothbay Fund Management sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q4 2022, closing a stake of 13,499 shares — an estimated $134K sold.

Boothbay Fund Management first reported a position in IBER.WS in Q2 2021 and held it in 6 quarters. The position peaked at $134K in Q3 2022. 33 funds tracked by Wall St. Rank hold IBER.WS as of Q4 2022.

Boothbay Fund Management reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 13,499 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q4 2022, an estimated $134K.
Boothbay Fund Management first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 6 quarters.
Boothbay Fund Management's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $134K in Q3 2022.
33 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.